25.16
-0.58 (-2.25%)
| Previous Close | 25.74 |
| Open | 26.02 |
| Volume | 581,493 |
| Avg. Volume (3M) | 820,698 |
| Market Cap | 1,161,717,760 |
| Price / Earnings (Forward) | 9.44 |
| Price / Sales | 1.70 |
| Price / Book | 1.54 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Profit Margin | -14.20% |
| Operating Margin (TTM) | 15.77% |
| Diluted EPS (TTM) | -2.15 |
| Quarterly Revenue Growth (YOY) | 3.30% |
| Quarterly Earnings Growth (YOY) | -35.50% |
| Total Debt/Equity (MRQ) | 82.08% |
| Current Ratio (MRQ) | 2.40 |
| Operating Cash Flow (TTM) | 189.39 M |
| Levered Free Cash Flow (TTM) | 163.38 M |
| Return on Assets (TTM) | 3.90% |
| Return on Equity (TTM) | -12.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Pacira BioSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.63 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 3.09% |
| % Held by Institutions | 112.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (HC Wainwright & Co., 158.35%) | Buy |
| Median | 28.50 (13.28%) | |
| Low | 24.00 (Barclays, -4.61%) | Buy |
| Average | 36.50 (45.07%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 25.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Apr 2025 | 65.00 (158.35%) | Buy | 26.27 |
| 28 Feb 2025 | 70.00 (178.22%) | Buy | 24.05 | |
| Needham | 08 Apr 2025 | 32.00 (27.19%) | Buy | 26.27 |
| 28 Feb 2025 | 32.00 (27.19%) | Buy | 24.05 | |
| Barclays | 28 Feb 2025 | 24.00 (-4.61%) | Buy | 24.05 |
| Truist Securities | 30 Jan 2025 | 25.00 (-0.64%) | Hold | 26.24 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |